The rebranded firm, now holding 94,675 ETH, is betting big on Ethereum’s long-term value, with backing from Polychain, Founders Fund, and key DeFi founders. According to a press release dated August 18, ETHZilla Corporation has officially completed its rebranding and…The rebranded firm, now holding 94,675 ETH, is betting big on Ethereum’s long-term value, with backing from Polychain, Founders Fund, and key DeFi founders. According to a press release dated August 18, ETHZilla Corporation has officially completed its rebranding and…

ETHZilla’s NASDAQ relaunch puts $419m Ethereum treasury in the spotlight

2025/08/19 04:25
2 min di lettura
Per feedback o dubbi su questo contenuto, contattateci all'indirizzo crypto.news@mexc.com.

The rebranded firm, now holding 94,675 ETH, is betting big on Ethereum’s long-term value, with backing from Polychain, Founders Fund, and key DeFi founders.

Summary
  • ETHZilla debuts on NASDAQ with a $419m Ethereum treasury, rebranding from biotech firm 180 Life Sciences.
  • Backed by Polychain, Founders Fund, and DeFi leaders, ETHZilla aims to be a major corporate ETH holder.

According to a press release dated August 18, ETHZilla Corporation has officially completed its rebranding and transition from biotech firm 180 Life Sciences to a dedicated Ethereum (ETH) treasury vehicle.

The company’s shares began trading under the new ticker “ETHZ” on the same day, marking a strategic shift toward accumulating and managing one of the largest corporate ETH holdings in public markets.

With 94,675 ETH acquired at an average price of $3,902 and now worth approximately $419 million, the move signals a growing institutional embrace of Ethereum as a treasury asset.

ETHZilla’s institutional backing and pivot into Ethereum

According to ETHZilla’s announcement, its treasury strategy is designed to leverage Ethereum’s dual role as both a store of value and a yield-generating asset. The company said it has partnered with Electric Capital to maximize returns through staking, DeFi lending, and liquidity provisioning, positioning the firm to benefit from Ethereum’s expanding utility beyond mere price appreciation.

The pivot from biotech to Ethereum treasury management came after ETHZilla raised $565 million in private funding, with backing from over 60 institutional and crypto-native investors.

The list features both a deep bench of both institutional capital and Ethereum-native builders. Polychain Capital, Electric Capital, and Peter Thiel’s Founders Fund anchor the institutional side, while key DeFi founders, including EigenLayer’s Sreeram Kannan, Lido’s Konstantin Lomashuk, and Compound’s Robert Leshner, lend credibility to the venture. Their participation suggests confidence not just in ETHZilla’s model, but in Ethereum’s long-term viability as a cornerstone of decentralized finance.

While ETHZilla’s treasury strategy dominates headlines, the company hasn’t abandoned its roots entirely. The company said its legacy biotech assets remain part of the portfolio, with plans to monetize intellectual property, and its gaming division continues to operate. This diversified approach could provide stability if crypto markets turn volatile, though the firm’s future now hinges on Ethereum’s performance.

Opportunità di mercato
Logo DeFi
Valore DeFi (DEFI)
$0.0001971
$0.0001971$0.0001971
-1.79%
USD
Grafico dei prezzi in tempo reale di DeFi (DEFI)

SPACEX(PRE) Launchpad

SPACEX(PRE) LaunchpadSPACEX(PRE) Launchpad

Register for a chance to win a free lucky draw

Disclaimer: gli articoli ripubblicati su questo sito provengono da piattaforme pubbliche e sono forniti esclusivamente a scopo informativo. Non riflettono necessariamente le opinioni di MEXC. Tutti i diritti rimangono agli autori originali. Se ritieni che un contenuto violi i diritti di terze parti, contatta crypto.news@mexc.com per la rimozione. MEXC non fornisce alcuna garanzia in merito all'accuratezza, completezza o tempestività del contenuto e non è responsabile per eventuali azioni intraprese sulla base delle informazioni fornite. Il contenuto non costituisce consulenza finanziaria, legale o professionale di altro tipo, né deve essere considerato una raccomandazione o un'approvazione da parte di MEXC.

Potrebbe anche piacerti

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Condividi
BitcoinEthereumNews2025/09/18 05:26
Bitcoin shorts risk $2.5 billion liquidation at $72K: Are bears in danger?

Bitcoin shorts risk $2.5 billion liquidation at $72K: Are bears in danger?

Bitcoin is poised for a reversal if ETF demand returns or a ceasefire occurs, potentially crushing short sellers in a massive price squeeze.
Condividi
Coin Telegraph2026/04/04 19:58
Robotics Automation Prototyping: Engineering Kinetic Agility into End-Effectors

Robotics Automation Prototyping: Engineering Kinetic Agility into End-Effectors

Inertia is the invisible tax on modern industrial throughput. Every millisecond a robotic arm spends decelerating, or waiting for high-frequency vibrations to settle
Condividi
Techbullion2026/04/02 18:25

RealStocks Now Live

RealStocks Now LiveRealStocks Now Live

Trade real U.S. stock via regulated brokerage